<DOC>
	<DOCNO>NCT01076088</DOCNO>
	<brief_summary>This study ass efficacy safety initial treatment sitagliptin metformin patient type 2 diabetes mellitus China . The primary hypothesis 24 week , initial co-administration treatment sitagliptin metformin provide great reduction hemoglobin A1C ( A1C ) compare initial treatment sitagliptin alone metformin alone .</brief_summary>
	<brief_title>Safety Efficacy Co-Administration Sitagliptin Metformin China ( MK-0431-121 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>type 2 diabetes mellitus male , female child , female agrees use birth control study antihyperglycemic agent ( AHA ) ( hemoglobin A1c [ A1C ] 7.511.0 % ) oral single AHA ( A1C 7.010.5 % ) lowdose AHA combination therapy ( A1C 7.010.0 % ) Patient type 1 diabetes mellitus ketoacidosis Patient take dipeptidyl peptidase4 ( DPP4 ) inhibitor ( sitagliptin ) Patient weight loss program maintenance phase weight loss medication Patient history liver disease , heart failure , heart disease , stroke , high blood pressure , blood disorder , cancer Patient HIV positive Patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>